Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.66 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899440 | 0.90 | TAS2R14 (0.63) | TAS2R14CXCR3MEN1KMT2AALDH1A1 | |
| SCHEMBL5899442 | 0.83 | PTPN1 (0.57) | TAS2R14MEN1KMT2ADAGLA | |
| SCHEMBL5899564 | 0.82 | HSD11B1 (0.51) | TAS2R14MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1168758 | 0.80 | TAS2R14 (1.00) | TAS2R14CXCR3MEN1KMT2APOLB | |
| SCHEMBL1279324 | 0.80 | TAS2R14 (1.00) | TAS2R14CXCR3MEN1KMT2APOLB | |
| SCHEMBL5899551 | 0.78 | TAS2R14 (0.56) | TAS2R14MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1170162 | 0.77 | TAS2R14 (0.92) | TAS2R14CXCR3MEN1KMT2APOLB | |
| SCHEMBL5295487 | 0.76 | TAS2R14 (0.64) | TAS2R14MEN1KMT2ADAGLAALDH1A1 | |
| SCHEMBL5899593 | 0.76 | KMT2A (0.54) | TAS2R14CXCR3MEN1KMT2APOLB | |
| SCHEMBL30640420 | 0.76 | THRB (0.74) | TAS2R14CXCR3MEN1KMT2ADAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025445-A1 | 11-Beta HSD1 inhibitors | WYETH | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025445-A1 | 11-Beta HSD1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | TAS2R14 4454/4885CXCR3 2880/4885MEN1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.